{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:45:19Z","timestamp":1768545919436,"version":"3.49.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.gtc.2020.01.012","type":"journal-article","created":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T07:06:50Z","timestamp":1585465610000},"page":"347-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Extrahepatic Manifestations of Chronic Viral C Hepatitis"],"prefix":"10.1016","volume":"49","author":[{"given":"Salvatore","family":"Petta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Crax\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib1","first-page":"161","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"LancetGastroenterolHepatol"},{"issue":"4","key":"10.1016\/j.gtc.2020.01.012_bib2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.28430","article-title":"The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics","volume":"63","author":"Rein","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gtc.2020.01.012_bib3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"Molnar","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2020.01.012_bib4","doi-asserted-by":"crossref","first-page":"564645","DOI":"10.1155\/2013\/564645","article-title":"Metabolic factors and chronic hepatitis C: a complex interplay","volume":"2013","author":"Macaluso","year":"2013","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.gtc.2020.01.012_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.gastro.2013.09.019","article-title":"Development and validation of a comorbidity scoring system for patients with cirrhosis","volume":"146","author":"Jepsen","year":"2014","journal-title":"Gastroenterology"},{"issue":"9539","key":"10.1016\/j.gtc.2020.01.012_bib6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(06)69374-4","article-title":"Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study","volume":"368","author":"Amin","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.gtc.2020.01.012_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","article-title":"Extrahepatic morbidity and mortality of chronic hepatitis C","volume":"149","author":"Negro","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2020.01.012_bib8","article-title":"EASL recommendations on treatment of hepatitis C 2015","author":"European Association for Study of Liver","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2020.01.012_bib9","first-page":"1","article-title":"Expert opinion on managing chronic HCV in patients with mixed cryoglobulinaemiavasculitis","volume":"23","author":"Zignego","year":"2018","journal-title":"AntivirTher"},{"issue":"4","key":"10.1016\/j.gtc.2020.01.012_bib10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","article-title":"Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study","volume":"61","author":"Gragnani","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gtc.2020.01.012_bib11","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib12","first-page":"518","article-title":"Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated CryoglobulinemiaVasculitis","volume":"17","author":"Cacoub","year":"2019","journal-title":"ClinGastroenterolHepatol"},{"issue":"1","key":"10.1016\/j.gtc.2020.01.012_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2017-03-771238","article-title":"Reversion of anergy signatures in clonal CD21(low) B cells of mixed cryoglobulinemia after clearance of HCV viremia","volume":"130","author":"Del Padre","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gtc.2020.01.012_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated CryoglobulinemiaVasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.gtc.2020.01.012_bib15","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1053\/j.gastro.2017.02.037","article-title":"Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced CryoglobulinemiaVasculitis","volume":"152","author":"Comarmond","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/hep.28387","article-title":"Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study","volume":"63","author":"Su","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","article-title":"The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection","volume":"67","author":"Mahale","year":"2018","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.gtc.2020.01.012_bib18","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.gtc.2020.01.012_bib19","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","article-title":"Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C","volume":"120","author":"Kawamura","year":"2007","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/apt.15101","article-title":"Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection","volume":"49","author":"Su","year":"2019","journal-title":"Aliment PharmacolTher"},{"issue":"21","key":"10.1016\/j.gtc.2020.01.012_bib21","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gtc.2020.01.012_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29364","article-title":"Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma","volume":"67","author":"Persico","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.gtc.2020.01.012_bib23","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2012.07.037","article-title":"Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement","volume":"57","author":"Schaefer","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.gtc.2020.01.012_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2002.30688","article-title":"Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease","volume":"35","author":"Forton","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2020.01.012_bib25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jhep.2004.07.022","article-title":"Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy","volume":"41","author":"Weissenborn","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2020.01.012_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(00)05270-3","article-title":"Evidence for a cerebral effect of the hepatitis C virus","volume":"358","author":"Forton","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2020.01.012_bib27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/gut.2010.217976","article-title":"Evidence for neuroinflammation and neuroprotection in HCV infectionassociated encephalopathy","volume":"60","author":"Bokemeyer","year":"2011","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.gtc.2020.01.012_bib28","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.27724","article-title":"Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials","volume":"61","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gtc.2020.01.012_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2016.02.042","article-title":"Sofosbuvir\/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial","volume":"65","author":"Younossi","year":"2016","journal-title":"JHepatol"},{"issue":"2","key":"10.1016\/j.gtc.2020.01.012_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jhep.2015.03.014","article-title":"Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir","volume":"63","author":"Younossi","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2020.01.012_bib31","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","article-title":"Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression","volume":"125","author":"Hui","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2020.01.012_bib32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","article-title":"Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis","volume":"134","author":"Moucari","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2020.01.012_bib33","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10620-012-2438-3","article-title":"Insulin sensitivity and variability in hepatitis C virus infection using direct measurement","volume":"58","author":"Mukhtar","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2020.01.012_bib34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/hep.23031","article-title":"Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C","volume":"50","author":"Vanni","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2020.01.012_bib35","doi-asserted-by":"crossref","first-page":"e931","DOI":"10.1053\/j.gastro.2009.11.050","article-title":"Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance","volume":"138","author":"Milner","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2020.01.012_bib36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-133-8-200010170-00009","article-title":"Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States","volume":"133","author":"Mehta","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2020.01.012_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/jhep.2003.50291","article-title":"Hepatitis C virus infection and incident type 2 diabetes","volume":"38","author":"Mehta","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gtc.2020.01.012_bib38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/liv.13194","article-title":"Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study","volume":"37","author":"Lin","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.gtc.2020.01.012_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1586\/egh.11.43","article-title":"Current understanding of insulin resistance in hepatitis C","volume":"5","author":"Kaddai","year":"2011","journal-title":"Expert Rev GastroenterolHepatol"},{"key":"10.1016\/j.gtc.2020.01.012_bib40","first-page":"1384","article-title":"Impaired IRS-1\/PI3- kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes","volume":"38","author":"Aytug","year":"2003","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep.22703","article-title":"Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C","volume":"49","author":"Arase","year":"2009","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.gtc.2020.01.012_bib42","first-page":"1379","article-title":"Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients","volume":"33","author":"Adinolfi","year":"2018","journal-title":"J\u00a0GastroenterolHepatol"},{"issue":"12","key":"10.1016\/j.gtc.2020.01.012_bib43","doi-asserted-by":"crossref","first-page":"e0209216","DOI":"10.1371\/journal.pone.0209216","article-title":"Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents","volume":"13","author":"Gualerzi","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib44","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13924","article-title":"Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure","volume":"90","author":"Lim","year":"2019","journal-title":"ClinEndocrinol (Oxf)"},{"issue":"9","key":"10.1016\/j.gtc.2020.01.012_bib45","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus","volume":"40","author":"Hum","year":"2017","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.gtc.2020.01.012_bib46","first-page":"952","article-title":"Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States","volume":"25","author":"Li","year":"2018","journal-title":"J\u00a0ViralHepat"},{"issue":"12","key":"10.1016\/j.gtc.2020.01.012_bib47","first-page":"1665","article-title":"Sustained Virological Response Is Associated with a Decreased Risk of Posttransplant Diabetes Mellitus in Liver Transplant Recipients with Hepatitis C-Related Liver Disease","volume":"24","author":"Roccaro","year":"2018","journal-title":"LiverTranspl"},{"issue":"4","key":"10.1016\/j.gtc.2020.01.012_bib48","first-page":"419","article-title":"Impact of Sustained Viral Response With Direct-Acting Agents on Glycemic Control and Renal Function in Hepatitis C Liver Transplant Recipients","volume":"16","author":"Saab","year":"2018","journal-title":"ExpClin Transplant"},{"issue":"1","key":"10.1016\/j.gtc.2020.01.012_bib49","first-page":"34","article-title":"Hepatitis C virus and lipid droplets: finding a niche","volume":"21","author":"Filipe","year":"2015","journal-title":"TrendsMol Med"},{"issue":"11","key":"10.1016\/j.gtc.2020.01.012_bib50","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1111\/j.1572-0241.2002.07056.x","article-title":"Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a","volume":"97","author":"Hofer","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib51","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.27424","article-title":"Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients","volume":"61","author":"Meissner","year":"2015","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2020.01.012_bib52","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0168-8278(12)60007-5","article-title":"The interaction of metabolic factors with HCV infection: does it matter?","volume":"56","author":"Bugianesi","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2020.01.012_bib53","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1053\/jhep.2002.36370","article-title":"Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response","volume":"36","author":"Kumar","year":"2002","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1016\/j.gtc.2020.01.012_bib54","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jhep.2016.06.011","article-title":"Hepatitis C virus infection and chronic kidney disease: Time for reappraisal","volume":"65","author":"Cacoub","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.gtc.2020.01.012_bib55","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/archinte.167.12.1271","article-title":"Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease","volume":"167","author":"Tsui","year":"2007","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib56","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/hep.29192","article-title":"Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study","volume":"66","author":"Lai","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gtc.2020.01.012_bib57","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2017.12.003","article-title":"Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis","volume":"68","author":"S\u00f6derholm","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib58","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.gtc.2020.01.012_bib59","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40121-017-0171-0","article-title":"Effect of Hepatitis C Treatment with Ombitasvir\/Paritaprevir\/R\u00a0+ Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials","volume":"6","author":"Mehta","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10.1016\/j.gtc.2020.01.012_bib60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40121-018-0218-x","article-title":"Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials","volume":"7","author":"Tran","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib61","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/gutjnl-2013-306102","article-title":"Cardiovascular diseases and HCV infection: a simple association or more?","volume":"63","author":"Petta","year":"2014","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.gtc.2020.01.012_bib62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1253\/circj.67.26","article-title":"Association between hepatitis C virus core protein and carotid atherosclerosis","volume":"67","author":"Ishizaka","year":"2003","journal-title":"Circ J"},{"key":"10.1016\/j.gtc.2020.01.012_bib63","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jhep.2007.01.021","article-title":"Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C","volume":"46","author":"Targher","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2020.01.012_bib64","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2012.01.051","article-title":"Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis","volume":"221","author":"Adinolfi","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.gtc.2020.01.012_bib65","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.25508","article-title":"Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations","volume":"55","author":"Petta","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2020.01.012_bib66","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/599371","article-title":"Hepatitis C virus infection and the risk of coronary disease","volume":"49","author":"Butt","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gtc.2020.01.012_bib67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijcard.2014.11.200","article-title":"Long-term risk of acute coronary syndrome in hepatitis C virus infected patients without antiviral treatment: A cohort study from an endemic area","volume":"181","author":"Tsai","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.gtc.2020.01.012_bib68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2013.08.003","article-title":"Chronic HCV infection is a risk factor of ischemic stroke","volume":"231","author":"Adinolfi","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.gtc.2020.01.012_bib69","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/STROKEAHA.110.598136","article-title":"Hepatitis C virus infection and increased risk of cerebrovascular disease","volume":"41","author":"Lee","year":"2010","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.gtc.2020.01.012_bib70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jhep.2014.09.022","article-title":"Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study","volume":"62","author":"Hsu","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.gtc.2020.01.012_bib71","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jhep.2014.05.032","article-title":"Chronic HCV infection increases cardiac left ventricular mass index in normotensive patients","volume":"61","author":"Perticone","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2020.01.012_bib72","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.gtc.2020.01.012_bib73","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2020.01.012_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2012.07.045","article-title":"Myocardial injury in patients with chronic hepatitis C infection","volume":"58","author":"Maruyama","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2020.01.012_bib75","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2018.02.015","article-title":"Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis","volume":"69","author":"Petta","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2020.01.012_bib76","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijcard.2018.04.058","article-title":"Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function","volume":"271","author":"Schmidt","year":"2018","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.gtc.2020.01.012_bib77","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/apt.14934","article-title":"Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study","volume":"48","author":"Novo","year":"2018","journal-title":"Aliment PharmacolTher"},{"key":"10.1016\/j.gtc.2020.01.012_bib78","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ahj.2017.10.024","article-title":"Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients","volume":"198","author":"Cacoub","year":"2018","journal-title":"Am Heart J"},{"issue":"10179","key":"10.1016\/j.gtc.2020.01.012_bib79","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855320300121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855320300121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:30:21Z","timestamp":1760178621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855320300121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0889855320300121"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2020.01.012","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extrahepatic Manifestations of Chronic Viral C Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2020.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}